Researchers Test New Botanical Drug That Could Silence Peanut Allergies

Main Category: Allergy
Also Included In: Nutrition / Diet;  Immune System / Vaccines
Article Date: 10 Feb 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

A new study finds that a botanical drug could provide the key to new treatments for peanut allergies. The findings are published online in The Journal of Allergy and Clinical Immunology.

Lead author Xiu-Min Li, MD, Associate Professor of Pediatrics and Director of Center for Chinese Herbal Therapy for Allergy and Asthma at Mount Sinai School of Medicine and colleagues found Food Allergy Herbal Formula (FAHF-2) produced long-term protection following treatment against peanut-induced anaphylaxis in mice. FAHF-2 treatment protected peanut allergic mice from anaphylaxis for more than 36 weeks after treatment was discontinued. This is one-quarter of the mouse lifespan. These findings update previous research done by Dr. Li and her colleagues, where the same drug was shown to be effective for preventing anaphylactic reactions for up to four weeks following treatment.

"Food allergy is a serious and sometimes fatal condition for which there is no cure," said Dr. Li. "Approximately 80% of fatal or near-fatal anaphylaxis cases are due to peanut allergy in this country. There is an urgent need for effective therapies to prevent and treat those who suffer from food allergies and FAHF-2 could prove to be a major advancement in this field."

FAHF-2 has received investigational new drug approval of the Food and Drug Administration and currently human clinical trials are being conducted at Mount Sinai to evaluate the safety and early efficacy of FAHF-2 on multiple food allergies including peanut, tree nut, fish and shellfish. "This study reinforces previous studies showing that this botanical drug has the potential to be developed into the first available and effective treatment for patients with peanut allergies and other food allergies," said study co-author Hugh Sampson, MD, Professor of Pediatrics at Mount Sinai School of Medicine. Dr. Sampson is also Director of the Jaffe Food Allergy Institute and Dean for Translational Biomedical Science at The Mount Sinai Medical Center.

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses The Mount Sinai Hospital and Mount Sinai School of Medicine. The Mount Sinai Hospital is one of the nation's oldest, largest and most-respected voluntary hospitals. Founded in 1852, Mount Sinai today is a 1,171-bed tertiary-care teaching facility that is internationally acclaimed for excellence in clinical care. Last year, nearly 50,000 people were treated at Mount Sinai as inpatients, and there were nearly 450,000 outpatient visits to the Medical Center.

Mount Sinai School of Medicine is internationally recognized as a leader in groundbreaking clinical and basic-science research, as well as having an innovative approach to medical education. With a faculty of more than 3,400 in 38 clinical and basic science departments and centers, Mount Sinai ranks among the top 20 medical schools in receipt of National Institute of Health (NIH) grants.

Mount Sinai Medical Center
1 Gustave Levy Pl.
New York
NY 10029
United States
http://www.mountsinai.org

• Additional
• References
• Citations